In September, the Iron Horse Labs project finally vanished from the Upper East Side market. Developer Taconic Partners sold the designated site at 309 East 94th Street, where an approximately 200,000 square foot Class A research facility was due to be built, to residential developer LCOR for $73 million. The sale marks another setback for the New York life sciences sector, where several laboratory assets across Manhattan and the surrounding boroughs were offloaded at a loss to owners outside the industry upon completion this year.
The development stands in sharp contrast to the momentum of 2020 and 2021, when the pandemic and sustained low interest rates channelled substantial investment into the biotechnology sector. Taconic had spun off its life sciences portfolio into subsidiary Elevate Research Properties in 2022 to hedge against what was then a weakening office market. While Manhattan office space has since seen a tangible recovery in demand, rental growth for research laboratories lagged behind. Today, only a single property remains in Elevate's New York portfolio.
Oversupply meets macroeconomic headwinds
Jonathan Schifrin, Senior Managing Director and head of life sciences at Savills in New York, describes the market situation as classic overdevelopment. Interest rate rises in 2022 dampened investor appetite, while cuts to federal research funding in 2025 placed additional strain on the industry. At the same time, newly delivered supply significantly outstripped demand from young start-ups. An industry report from JLL put the availability rate in New York City at 37 per cent in June, the highest figure nationwide.
Schifrin views the current development as an overdue market correction rather than a permanent crisis. Third-quarter data from Savills shows a decline in the vacancy rate for New York laboratories from 32.5 per cent in the previous quarter to 22.8 per cent, primarily driven by conversions and sales. The citywide total stock stands at 3.1 million square feet, with no new schemes currently under construction.
Subdued optimism driven by rising leasing activity
Leasing take-up in the Greater New York area reached 87,158 square feet in the third quarter of 2026 according to CoStar, up from 30,933 square feet in the previous quarter and just 9,883 square feet in the third quarter of 2025. Across the first nine months of 2026, volume totalled 143,098 square feet, compared with 61,433 square feet in the equivalent period of the previous year. Victor Rodriguez, Senior Director of Analytics at CoStar, considers the market to be in a very early stage of stabilisation, but stresses that it is still too early to speak of a full recovery.
- —Largest deal of the year: Jackson Laboratory leased 41,000 square feet at the Hudson Research Center in Hell's Kitchen in January.
- —Successful full occupancy: Rover Diagnostics secured 15,763 square feet in the InnoLabs property in Long Island City, Queens.
- —Municipal support programmes: The Economic Development Corporation reaffirmed its $1 billion budget for the LifeSci NYC initiative, despite planned internal headcount reductions.
Industry observers attribute the success of individual schemes primarily to their completion timing. While developments brought to market late had to bear the full brunt of the cycle, established assets continue to secure solid occupier deals. Whether the market recovers sustainably will depend on the resilience of demand in the coming quarters.














